Abstract: Engineered, reinforced leather materials (engineered leathers) including a composite of a fibrous matrix that has been tanned to allow crosslinking of the fibrous matrix to the collagen formed by cultured cells (e.g., fibroblasts). These engineered leathers may be referred to as fiber-reinforced biological tissue composites. Also described herein are methods of making such fiber-reinforced biological tissue composites.

Abstract: The disclosure concerns high molecular weight hyaluronic acid compositions that release hyaluronic acid at controlled rates. The compositions may achieve improved retention and duration of hyaluronic acid in the body, and may be used in methods of treating tissues throughout the body. Compositions, methods of treating, and methods of making are described.

Abstract: The invention is directed to a composite material comprising a biofabricated material and a secondary component. The secondary component may be a porous material, such as a sheet of paper, cellulose, or fabric that has been coated or otherwise contacted with the biofabricated material. The biofabricated material comprises a uniform network of crosslinked collagen fibrils and provides strength, elasticity and an aesthetic appearance to the composite material.

Abstract: A binderless zeolite adsorbent for separation of oxygen from a gaseous stream. The adsorbent is a blend of a lithium exchanged zeolite 13X, a lithium exchanged low silica zeolite X zeolite, and halloysite clay. Also disclosed is a process of making the binderless zeolite adsorbent. Further disclosed is a process for production of oxygen from a gaseous stream utilizing the binderless zeolite adsorbent.

Abstract: A biofabricated material comprising a network of crosslinked collagen fibrils produced from recombinant collagen that contains substantially no 3-hydroxyproline residues is disclosed. This material is composed of collagen which is also a major component of natural leather and is produced by a process of fibrillation of collagen molecules into fibrils, crosslinking the fibrils and lubricating the crosslinked fibrils. Unlike natural leathers, this biofabricated material exhibits non-anisotropic (not directionally dependent) physical properties, for example, a sheet of biofabricated material can have substantially the same elasticity or tensile strength when stretched or stressed in different directions. Unlike natural leather, it has a uniform texture that facilitates uniform uptake of dyes and coatings. Aesthetically, it produces a uniform and consistent grain for ease of manufacturability.

Abstract: The invention is directed to a composite material comprising a biofabricated material and a secondary component. The secondary component may be a porous material, such as a sheet of paper, cellulose, or fabric that has been coated or otherwise contacted with the biofabricated material. The biofabricated material comprises a uniform network of crosslinked collagen fibrilsand provides strength, elasticity and an aesthetic appearance to the composite material.

Abstract: Described herein is a method for producing a biofabricated material from collagen or collagen-like proteins. The collagen or collagen-like proteins are isolated from animal sources or produced by recombinant DNA techniques or by chemical synthesis. The collagen or collagen-like proteins are fibrillated, crosslinked, dehydrated and lubricated thus forming the biofabricated material having a substantially uniform network of collagen fibrils.

Abstract: The invention herein provides biofabricated materials having zonal properties and methods of making biofabricated materials having zonal properties.

Abstract: The invention concerns methods of delivering a hydrogel to the heart, comprising: introducing a hydrogel composition into a subject, said hydrogel comprising components mixed prior to introduction; the introducing being performed such that the hydrogel composition resides between the epicardium and the pericardium of the subject. In some embodiments, the injection is performed using a syringe or catheter.

Abstract: A biofabricated material containing a network of crosslinked collagen fibrils is disclosed. This material is composed of collagen which is also a major component of natural leather and is produced by a process of fibrillation of collagen molecules into fibrils, crosslinking the fibrils and lubricating the crosslinked fibrils. Unlike natural leathers, this biofabricated material exhibits non-anisotropic (not directionally dependent) physical properties, for example, a sheet of biofabricated material can have substantially the same elasticity or tensile strength when stretched or stressed in different directions. Unlike natural leather, it has a uniform texture that facilitates uniform uptake of dyes and coatings. Aesthetically, it produces a uniform and consistent grain for ease of manufacturability. It can have substantially identical grain, texture and other aesthetic properties on both sides distinct from natural leather where the grain increases from one side (e.g.

Abstract: Described herein are three dimensionally shaped biofabricated materials and method of making three dimensionally shaped biofabricated materials.

Abstract: The invention is directed to a method for producing a composite material comprising a biofabricated material and a secondary component. The secondary component may be a porous material, such as a sheet of paper, cellulose, or fabric that has been coated or otherwise contacted with the biofabricated material. The biofabricated material comprises a uniform network of crosslinked collagen fibrils and provides strength, elasticity and an aesthetic appearance to the composite material.

Abstract: The invention is directed to a method for producing a composite material comprising a biofabricated material and a secondary component. The secondary component may be a porous material, such as a sheet of paper, cellulose, or fabric that has been coated or otherwise contacted with the biofabricated material. The biofabricated material comprises a uniform network of crosslinked collagen fibrils and provides strength, elasticity and an aesthetic appearance to the composite material.

Abstract: The invention is directed to a composite material comprising a biofabricated material and a secondary component. The secondary component may be a porous material, such as a sheet of paper, cellulose, or fabric that has been coated or otherwise contacted with the biofabricated material. The biofabricated material comprises a uniform network of crosslinked collagen fibrils and provides strength, elasticity and an aesthetic appearance to the composite material.

Abstract: Described herein is a method for producing a biofabricated material from collagen or collagen-like proteins which are recombinantly produced and which contain substantially no 3-hydroxyproline. The collagen or collagen-like proteins are isolated from animal sources, or produced by recombinant DNA techniques or by chemical synthesis. The collagen or collagen-like proteins are fibrillated, crosslinked, dehydrated and lubricated thus forming the biofabricated material having a substantially uniform network of collagen fibrils.

Abstract: A biofabricated material containing a network of crosslinked collagen fibrils is disclosed. This material is composed of collagen which is also a major component of natural leather and is produced by a process of fibrillation of collagen molecules into fibrils, crosslinking the fibrils and lubricating the crosslinked fibrils. Unlike natural leathers, this biofabricated material exhibits non-anisotropic (not directionally dependent) physical properties, for example, a sheet of biofabricated material can have substantially the same elasticity or tensile strength when stretched or stressed in different directions. Unlike natural leather, it has a uniform texture that facilitates uniform uptake of dyes and coatings. Aesthetically, it produces a uniform and consistent grain for ease of manufacturability. It can have substantially identical grain, texture and other aesthetic properties on both sides distinct from natural leather where the grain increases from one side (e.g.

Abstract: A biofabricated material containing a network of crosslinked collagen fibrils is disclosed. This material is composed of collagen which is also a major component of natural leather and is produced by a process of fibrillation of collagen molecules into fibrils, crosslinking the fibrils and lubricating the crosslinked fibrils. Unlike natural leathers, this biofabricated material exhibits non-anisotropic (not directionally dependent) physical properties, for example, a sheet of biofabricated material can have substantially the same elasticity or tensile strength when stretched or stressed in different directions. Unlike natural leather, it has a uniform texture that facilitates uniform uptake of dyes and coatings. Aesthetically, it produces a uniform and consistent grain for ease of manufacturability. It can have substantially identical grain, texture and other aesthetic properties on both sides distinct from natural leather where the grain increases from one side (e.g.

Abstract: The invention herein provides biofabricated materials having zonal properties and methods of making biofabricated materials having zonal properties.

Abstract: The invention herein provides biofabricated leather materials, solutions comprising collagen that can be used to create biofabricated leather materials, articles comprising biofabricated leather materials applied to portions of a substrate in a pattern or a design such a lace like pattern, and/or that serve to join end portions of one or more substrates, e.g., to replace stitching and/or adhesives, and methods thereof.

Abstract: The invention concerns compositions comprising: (i) biocompatible hydrogel, comprising a plurality of cross-linkers connecting backbone components of the hydrogel; wherein the hydrogel is cross-linked utilizing a cross-linker comprising a peptide sequence that is capable of being degraded by a matrix metalloproteinase; said inhibitor being effective as a treatment of a condition related to the presence of the matrix metalloproteinase; wherein the hydrogel encapsulates and retains the inhibitor within the intact hydrogel through non-covalent interactions; wherein the hydrogel comprises one or more of hyaluronic acid, sulfated hyaluronic acid, sulfonated hyaluronic acid, dextran, dextran sulfate, sulfonated dextran, chondroitin sulfate, heparin and heparan sulfate; (ii) pentosan polysulfate (PPS) and (iii) optionally, a therapeutic agent comprising an inhibitor of matrix metalloproteinase.